Accent on RNA
How Accent Therapeutics plans to use RNA epigenetics to treat cancer
With its debut Friday with a $40 million series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive cancer by modifying RNA, rather than DNA, to alter gene expression. It plans to target the enzymes with small molecules.
DNA- and histone-modifying enzymes, such as histone deacetylases (HDACs), have long been